In the first quarter of this year, Cologuard has received coverage from five commercial health plans. “As adoption of Cologuard grows rapidly among leading insurance providers, Exact Sciences is ...

Cologuard is getting an upgrade soon. An updated at-home screening test, called Cologuard Plus, is expected to be available in June 2025. Cologuard Plus is a more sensitive version of the original ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...

Exact Sciences Corporation EXAS is well-poised to grow in the coming quarters, courtesy of its continuous investment in R&D ...

Revenue guidance for 2025 was raised to $3.07 to $3.12 billion, up $40 million at the midpoint. Q2 revenue is projected between $765 million and $780 million. Screening revenue for 2025 is now ...

An ongoing theme among medical marketing is the increasingly common embrace of Spanish-language marketing by health brands. Considering there are more than 41 million Spanish speakers in the U.S., ...